AGIOS PHARMACEUTICALS, INC. Marketable Securities, Unrealized Gain (Loss)
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Marketable Securities, Unrealized Gain (Loss) of $5.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-16.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2017-02-16
- AGIOS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for fiscal 2016 was $5.00K.
- AGIOS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for fiscal 2015 was -$261.00K.
- AGIOS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for fiscal 2014 was -$71.00K, a 543.75% decline from fiscal 2013.
- AGIOS PHARMACEUTICALS, INC. marketable securities, unrealized gain (loss) for fiscal 2013 was $16.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|
| 2016-12-31 | $5.00K 10-K · filed 2017-02-16 |
| 2015-12-31 | -$261.00K 10-K · filed 2017-02-16 |
| 2014-12-31 | -$71.00K 10-K · filed 2017-02-16 |
| 2013-12-31 | $16.00K 10-K · filed 2016-02-26 |
| 2012-12-31 | -$25.00K 10-K · filed 2015-02-24 |
| 2011-12-31 | $31.00K 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |